IPO Update: What A Difference A (Pandemic) Year Makes

COVID-19 Paralyzed Market In Q1 2020 But Fortunes Reversed In 2021

Just nine drug developers went public in the US during the first quarter of last year, but with the industry boosted by pandemic response, 32 biopharma companies launched IPOs in Q1 of this year.

IPO (Initial Public Offering) letters hanging from strings
32 biopharma companies went public in the US in Q1, raising $5.2bn and generating an 11% average return • Source: Shutterstock

The market for initial public offerings in the US was vastly different in the first quarter of 2020 than it was during the same period of 2021.

Uncertainty related to COVID-19 shut down global financial markets in Q1 of last year, bringing initial public offerings to a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

More from Business

How Teva Is Expanding Innovation To Fuel ‘Pivot To Growth’

 

Teva VP-global R&D and chief medical officer Eric Hughes talked to Scrip about building the company’s innovative pipeline in its growth-acceleration phase.

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By 

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By 

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.